CSL (ASX:CSL) Net Income From Continuing Operations : A$3,768 Mil (TTM As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is CSL Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. CSL's net income from continuing operations for the six months ended in Dec. 2023 was A$2,868 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was A$3,768 Mil.

CSL Net Income From Continuing Operations Historical Data

The historical data trend for CSL's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Net Income From Continuing Operations Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income From Continuing Operations

Get a 7-Day Free Trial

2,762.93

3,046.52

3,106.50

3,208.44

3,343.56

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															2,460.90	703.53	2,430.78	899.66	2,868.48

CSL Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3,768 Mil.

CSL (ASX:CSL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

CSLLY:USA CMXHF:USA CSJ:Germany

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.